A Molecular Basis of Analgesic Tolerance to Cannabinoids

Clinical usage of cannabinoids in chronic pain states is limited by their central side effects and the pharmacodynamic tolerance that sets in after repeated dosage. Analgesic tolerance to cannabinoids in vivo could be caused by agonist-induced downregulation and intracellular trafficking of cannabinoid receptors, but little is known about the molecular mechanisms involved. We show here that the type 1 cannabinoid receptor (CB1) interacts physically with G-protein-associated sorting protein 1 (GASP1), a protein that sorts receptors in lysosomal compartments destined for degradation. CB1–GASP1 interaction was observed to be required for agonist-induced downregulation of CB1 in spinal neurons ex vivo as well as in vivo. Importantly, uncoupling CB1 from GASP1 in mice in vivo abrogated tolerance toward cannabinoid-induced analgesia. These results suggest that GASP1 is a key regulator of the fate of CB1 after agonist exposure in the nervous system and critically determines analgesic tolerance to cannabinoids.

[1]  Neil A. McDonald,et al.  An Essential Role for Constitutive Endocytosis, but Not Activity, in the Axonal Targeting of the CB1 Cannabinoid Receptor , 2007, Molecular Pharmacology.

[2]  M. Klugmann,et al.  Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain , 2006, Nature Medicine.

[3]  J. Rossier,et al.  Constitutive Activation Drives Compartment-Selective Endocytosis and Axonal Targeting of Type 1 Cannabinoid Receptors , 2006, The Journal of Neuroscience.

[4]  Ken Mackie,et al.  Cannabinoid receptors as therapeutic targets. , 2006, Annual review of pharmacology and toxicology.

[5]  A. Bonci,et al.  Dopamine responsiveness is regulated by targeted sorting of D2 receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Cebeira,et al.  Cannabinoid tolerance and dependence: A review of studies in laboratory animals , 2005, Pharmacology Biochemistry and Behavior.

[7]  T. Rubino,et al.  Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects , 2005, Journal of neurochemistry.

[8]  J. Jage.  Opioid tolerance and dependence — do they matter? , 2005, European journal of pain.

[9]  B. Ersbøll,et al.  A Library of 7TM Receptor C-terminal Tails , 2004, Journal of Biological Chemistry.

[10]  P. Seeburg,et al.  The AMPA Receptor Subunits GluR-A and GluR-B Reciprocally Modulate Spinal Synaptic Plasticity and Inflammatory Pain , 2004, Neuron.

[11]  M. Sheng,et al.  PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.

[12]  V. Wimmer,et al.  Targeted in vivo expression of proteins in the calyx of Held , 2004, Pflügers Archiv.

[13]  J. Rossier,et al.  Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor* , 2004, Journal of Biological Chemistry.

[14]  C. Bass,et al.  Reversal of Δ9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors , 2004 .

[15]  S. Offermanns,et al.  Plexin-B1/RhoGEF–mediated RhoA activation involves the receptor tyrosine kinase ErbB-2 , 2004, The Journal of cell biology.

[16]  D. Selley,et al.  Signaling pathways involved in the development of cannabinoid tolerance. , 2004, Trends in pharmacological sciences.

[17]  F. Simonin,et al.  Identification of a novel family of G protein‐coupled receptor associated sorting proteins , 2004, Journal of neurochemistry.

[18]  F. Lang,et al.  Channel-induced apoptosis of infected host cells—the case of malaria , 2004, Pflügers Archiv.

[19]  J. de Vry,et al.  Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development , 2004, Behavioural pharmacology.

[20]  J. W. Brooks,et al.  Cannabinoids and pain , 2003 .

[21]  S. Oess,et al.  Spinal upregulation of the nitric oxide synthase-interacting protein NOSIP in a rat model of inflammatory pain , 2003, Neuroscience Letters.

[22]  M. Kay,et al.  Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  L. Iversen,et al.  Cannabis and the brain. , 2003, Brain : a journal of neurology.

[24]  S. Welch,et al.  The Role of Several Kinases in Mice Tolerant to Δ9-Tetrahydrocannabinol , 2003, Journal of Pharmacology and Experimental Therapeutics.

[25]  P. Massi,et al.  Cellular mechanisms of Δ9‐tetrahydrocannabinol behavioural sensitization , 2003 .

[26]  R. Kotin,et al.  Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian Brain , 2002, Journal of Virology.

[27]  M. von Zastrow,et al.  Modulation of Postendocytic Sorting of G Protein-Coupled Receptors , 2002, Science.

[28]  C. Salio,et al.  Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord , 2002, Neuroscience.

[29]  Jamie Fong,et al.  Regulation of Opioid Receptor Trafficking and Morphine Tolerance by Receptor Oligomerization , 2002, Cell.

[30]  Sharon Anavi-Goffer,et al.  Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons , 2001, The Journal of Neuroscience.

[31]  M. Zastrow,et al.  Downregulation of G protein-coupled receptors , 2000, Current Opinion in Neurobiology.

[32]  K. Mackie,et al.  Internalization and Recycling of the CB1 Cannabinoid Receptor , 1999, Journal of neurochemistry.

[33]  K. Mackie,et al.  Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization , 1999, The Journal of Neuroscience.

[34]  S. Coughlin,et al.  Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[36]  D. Jasinski.  Tolerance and dependence to opiates , 1997, Acta anaesthesiologica Scandinavica.

[37]  M. Kaghad,et al.  An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.

[38]  G. Gebhart,et al.  Characterization of the role of spinal n-methyl-d-aspartate receptors in thermal nociception in the rat , 1993, Neuroscience.

[39]  S. Hunt,et al.  Fluoride-resistant acid phosphatase-containing neurones in dorsal root ganglia are separate from those containing substance P or somatostatin , 1982, Neuroscience.

[40]  R. Herning,et al.  Clinical Relevance of Cannabis Tolerance and Dependence , 1981, Journal of clinical pharmacology.

[41]  P. Sexton,et al.  Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. , 2006, Annals of the New York Academy of Sciences.

[42]  G. Marsicano,et al.  Neuromodulatory functions of the endocannabinoid system. , 2006, Journal of endocrinological investigation.

[43]  A. Lichtman,et al.  Cannabinoid tolerance and dependence. , 2005, Handbook of experimental pharmacology.

[44]  A. Hohmann,et al.  Cannabinoid mechanisms of pain suppression. , 2005, Handbook of experimental pharmacology.

[45]  C. Bass,et al.  Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. , 2004, European Journal of Pharmacology.

[46]  P. Massi,et al.  Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization. , 2003, European Journal of Neuroscience.

[47]  M. von Zastrow.  Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. , 2003, Life sciences.

[48]  M. Klugmann,et al.  Development and optimization of adeno-associated virus vector transfer into the central nervous system. , 2003, Methods in molecular medicine.

[49]  S. Welch,et al.  The Role of Several Kinases in Mice Tolerant to (cid:1) 9 Tetrahydrocannabinol , 2003 .

[50]  A. Rice,et al.  Cannabinoids and pain. , 2007, Handbook of experimental pharmacology.